Key result
Low-dose ASA and dipyridamole reduced the mean size of platelet thrombi by about 45% and 17% respectively, with their combination producing an additive effect.
Why the study?
Does the combination of acetylsalicylic acid and dipyridamole reduce ex vivo platelet thrombus formation in healthy subjects?
Population
96 healthy subjects
Comparison
Acetylsalicylic acid, dipyridamole, or their… vs Placebo
Design
RCT, randomized, double-blind
Follow-up
3.5 days
Authors
Loading...
Provides pharmacologic rationale for combined ASA-dipyridamole in stroke prevention; confirms additive platelet inhibition in RCT of healthy subjects.
RCT (n=96)
Double-blind
randomized
Does the combination of acetylsalicylic acid and dipyridamole reduce ex vivo platelet thrombus formation in healthy subjects?
The combination of low-dose acetylsalicylic acid and dipyridamole has an additive inhibitory effect on platelet thrombus formation ex vivo, providing a pharmacologic rationale for their combined use in stroke prevention.
Thomas Müller (2001) conducted an RCT in healthy subjects (n=96). Acetylsalicylic acid (ASA) and dipyridamole vs. placebo was evaluated on size and number of platelet thrombi. Low-dose ASA and dipyridamole reduced the mean size of platelet thrombi by about 45% and 17% respectively, with their combination producing an additive effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: